Seroprevalence of hepatitis B and C viruses and risk factors in HIV infected children at the felgehiwot referral hospital, Ethiopia

BMC Research Notes

Getachew Kahsu²  Mulugeta Kibret³  Wondemagegn Mulu¹  Yohanes Zenebe¹  Bayeh Abera¹ 

[1] Department of Medical Microbiology, Parasitology and Immunology, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia;Bahir Dar Regional Health Research Laboratory Center, Bahir Dar, Ethiopia;Department of Biology, Science College, Bahir Dar University, Bahir Dar, Ethiopia

关键词: Children;    ALT;    HIV;    HCV;    HBV;   

Others  :  1118247
DOI  :  10.1186/1756-0500-7-838

 received in 2014-09-16, accepted in 2014-11-18,  发布年份 2014

【 摘 要 】

Background

Liver hepatitis due to Hepatitis B (HBV) and hepatitis C virus (HCV) co-infection is the leading cause of morbidity and mortality in HIV infected children and it is more severe in resource poor settings. Data on seroprevalence of HBV and HCV among HIV infected children are scarce in Ethiopia. This study was conducted to determine seroprevalence and risk factors of HBV and HCV and its effect on liver enzyme among HIV-positive children aged 18 months to 15 years attending the paediatric HIV care and treatment clinic at Felege Hiwot referral hospital, Ethiopia.

Methods

A cross-sectional study was conducted in May, 2014. Demographic and risk factors were collected using a structured questionnaire. Hepatitis B surface antigen (HBsAg) and anti-HCV antibodies were detected using an enzyme linked immunosorbent assay (ELISA). Alanine aminotransferase (ALT) levels were determined. The results were analyzed using descriptive and logistic regression.

Results

A total of 253 HIV positive children, boys (52.5%) and girls (47.5%) took part in the study. The median age of the children was 11 years. Overall, 19 (7.5%) of HIV infected children were positive either for HBsAg or anti-HCV antibodies. The seroprevalence of HBV and HCV were 2.0% and 5.5%, respectively. All HBsAg positive children were in older age groups (11-15years). Seroprevalence of HCV was higher in children from urban (7.7%) than rural (1.2%) residents (P = 0.02). Overall, 29 (12.1%) of children had elevated ALT. Of these, 31.5% were from HBsAg or anti-HCV antibody positive children whereas 9.8% were from hepatitis B or C virus negative children (P = 0.001). Multivariate logistic regression showed that being positive for HBsAg or anti-HCV antibody (AOR: 4.7(95% CI: 1.5-13.5) was significantly associated with elevated ALT.

Conclusion

HBV and HCV co-infections are common in HIV positive children. In HIV positive children, HBV and HCV co-infection were associated with elevate ALT. Routine screening for HBV and HCV in HIV infected children should be implemented.

【 授权许可】

   
2014 Abera et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Matthews CP, Geretti AM, GoulderP JR, Klenerman P: Epidemiology of and impact of HIV coinfection with hepatitis B andHepatitis C viruses in Sub-Saharan Africa. J Clin Virol 2014, 61:20-33.
• [2]Federal Ministry of Health (FMOH): Country Progress Report on HIV/AIDS Response. Addis Ababa, Ethiopia: National HIV/AIDS Prevention and Control Office; 2012.
• [3]Alter MJ: Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006, 44:S6-S9.
• [4]Chu CJ, Lee SD: Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008, 23:512-520.
• [5]Barth RE, Huijgen Q, Taljaard J, Hoepelman AI: Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis 2010, 14:e1024-e1031.
• [6]Dessie A, Abera B, Wale F: Seroprevalence of major blood-borne infections among blood donors at Felege Hiwot referral hospital, northwest Ethiopia. Ethiop J Health Dev 2007, 21:68-69.
• [7]Gelaw B, Mengistu Y: Prevalence of HBV, HCV and malaria parasites among blood donors in Amhara and Tigray regional states. Ethiop J Health Dev 2007, 22:3-7.
• [8]Gunn RA, Murray PJ, Ackers ML, Hardison WG, Margolis HS: Screening for chronic hepatitis B and C virus infections in an urban sexually transmitted disease clinic - rationale for integrating services. Sex Transm Dis 2001, 28:166-170.
• [9]Andreoni M, Giacometti A, Maida I, Meraviglia P, Ripamonti D, Sarmati L: HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications. Eur Rev Med Pharmacol Sci 2012, 16:1473-1483.
• [10]Tien PC: Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the veterans affairs hepatitis C resource cemter program and national hepatitis C program office. Am J Gastroenterol 2005, 100:2338-2354.
• [11]World Health Organization (WHO): Hepatitis C. Geneva: WHO; 2003.
• [12]Tsuchiya N, Pathipvanich P, Rojanawiwat A, Wichukchinda N, Koga I, Koga M, Auwanit W, Kilgore PE, Ariyoshi K, Sawanpanyalert P: Chronic hepatitis B and C co-infection increased all-cause mortality in HAART-naive HIV patients in northern Thailand. Epidemiol Infect 2012. 10.1017/S0950268812002397 Cambridge University Press 2012
• [13]World Health Organization (WHO): Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. Geneva: WHO; 2010:1-63.
• [14]Zenebe H, Mulu W, Yimer M, Abera B: Sero-prevalence and risk factors of hepatitis B virus and human immunodeficiency virus infection among pregnant women in Bahir Dar city, Northwest Ethiopia: a cross sectional study. BMC Infect Dis 2014, 14:118-125. BioMed Central Full Text
• [15]Federal Ministry of Health (FMO): Guidelines for Paediatric HIV/AIDS Care and Treatment in Ethiopia. Ethiopia: Federal HIV/AIDS Prevention and Control Office Federal Ministry of Health; 2008.
• [16]Assefa Y, Kiflie A, Tesfaye D, Hailemariam D, Kloos H, Edwin W, Laga M, Damme WV: Outcomes of antiretroviral treatment program in Ethiopia: retention of patients in care is a major challenge and varies across health facilities. BMC Health Serv Res 2011, 11:81-88. BioMed Central Full Text
• [17]Katabuka M, Mafuta ME, Ngoma AM, Beya PM, Yuma S, Aketi L, Kayembe K, Gini JR: Prevalence and risk factors for hepatitis C virus, hepatitis B virus and immunodeficiency virus in transfused children in Kinshasa. Indian J Pediatr 2013, 80:659-662.
• [18]Telatela SP, Matee MI, Munubhi EK: Seroprevalence of hepatitis B and C viral co-infections among children infected withhuman immunodeficiency virus attending the paediatric HIV care and treatment centerat Muhimbili National Hospital in Dar-es Salaam, Tanzania. BMC Public Health 2007, 7:338. doi:10.1186/1471-2458-7-338 BioMed Central Full Text
• [19]Nwolisa E, Mbanefo F, Ezeogu J, Amadi P: Prevalence of hepatitis B co-infection amongst HIV infected children attending a care and treatment centre in Owerri, South-eastern Nigeria. Pan Afr Med J 2013, 14:89.
• [20]Anigilaje EA, Olutola A: Prevalence and clinical and immunovirological profile of human immunodeficiency virus-hepatitis B coinfection among children in an antirethroviral therapy prohramme in Benue State, Nigeria. ISRN Pediatr 2013., 2013doi.org/10.1155/2013/932697
• [21]Ikpeme EE, Etukudo O, Ekrikpo UE: Seroprevalence of HBV and HIV co-infection in children and outcomes following highly active antirethroviral therapy (HAART) in Uyo, South-south Nigeria. Afr Health Sci 2013, 13:955-961.
• [22]Jobarteh M, Malfroy M, Peterson I, Jeng A, Sarge-Njie R, Alabi A, Peterson K, Cotton M, Hall A, Jones SR, Whittle H, Tedder R, Jaye A, Mendy M: Seroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected Gambians. Virol J 2010, 7:230. BioMed Central Full Text
• [23]Mulu W, Gidey B, Chernet A, Alem G, Abera B: Hepatotoxicity and associated risk factors in HIV-infected patients receiving antiretroviral therapy at FelegHiwot referral hospital, Bahir Dar Ethiopia. Ethiop J Health Sci 2013, 23:217-226.
• [24]Tramuto F, Maida CM, Colomba GME, Carlo PD, Vitale F: Prevalence of occult hepatitis B virus infection in a cohort of HIV-positive patients resident in Sicily, Italy. Biomed Res Int 2013 2013. doi.org/10.1155/2013/859583
• [25]Toussi SS, Abadi J, Rosenberg M, Levanon D: Prevalence of hepatitis B and C virus infections in children infected with HIV. HIV/AIDS 2007, 45:795-798.
• [26]Karoney MJ, Siika AM: Hepatitis C virus (HCV) infection in Africa: a review. Pan Afr Med J 2013, 14:44. doi:10.11604
• [27]Eze JC, Ibeziako NS, Ikefuna AN, Nwokye IC, Uleanya ND, IIechukwu GC: Prevalence and risk factors for hepatitis C and human immunodeficiency virus coinfection among children in Enugu Nigeria. Afr J Infect Dis 2014, 8:5-8.
• [28]Ayele W, Nokes DJ, Abebe A, Messele T, Dejene A, Enquselassie F, Rinke de Wit TF, Fontanet AL: Higher prevalence of anti-HCV antibodies among HIV-positive compared to HIV-negative inhabitants of Addis Ababa, Ethiopia. J Med Virol 2002, 68:12-17.
• [29]Hadush H, Gebre-Selassie S, Mihret A: Hepatitis C virus and human immunodeficiency virus coinfection among attendants of voluntary counseling and testing centre and HIV follow up clinics in Mekelle Hospital. Pan Afr Med J 2013, 14:107. doi:10.11604/pamj.2013.14.107
• [30]Muriuki BM, Gicheru MM, Wachira D, Nyamache AK, Khamadi SA: Prevalence of hepatitis B and C viral co-infections among HIV-1 infected individuals in Nairobi, Kenya. BMC Res Notes 2013, 6:363. BioMed Central Full Text
• [31]UNICEF: Policy Brief: Abandoning FGM/C (Female Genital Mutilation/Cutting) in Ethiopia. UNICEF: Ethiopia; 2013.
• [32]Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, Chaisson R, Grant AD, Fielding KL, Thio CL: Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008, 47:1479-1485.